Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Study shows SARS-CoV-2 antibodies persist for one-year post-infection with protection from other variants

Researchers discussed the stability of spike antibody titers mounted against SARS-CoV-2 infection, and their ability to protect from infection with antigenically similar variants.

4 Apr 2022

Evidence SARS-CoV-2 undergoes ADAR-mediated A-to-I RNA editing in human cells

In a recent study published in the journal PLOS Genetics, researchers explored severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) ribonucleic acid (RNA) editing in host cells.

4 Apr 2022

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.

4 Apr 2022

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or "bad" cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.

3 Apr 2022

Natural compound found in cardamom shows promise for treating triple-negative breast cancer

Cardamonin - a natural compound found in the spice cardamom and other plants - could have therapeutic potential for triple-negative breast cancer, according to a new study using human cancer cells.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Results from a preclinical study add new evidence that a multi-mineral dietary supplement known as Aquamin could be a simple and effective way to reduce the long-term health consequences of non-alcoholic fatty liver disease.

3 Apr 2022

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

3 Apr 2022

Analysis of antioxidants, stress markers in the blood could lead to new diagnostic tool for breast cancer

A new study that analyzes levels of antioxidants and stress markers in the blood could lead to a new diagnostic tool for breast cancer. The research will be presented this week in Philadelphia at the American Physiological Society's annual meeting at Experimental Biology 2022.

2 Apr 2022

Smokers have lower odds of surviving a heart attack than non-smokers

Smokers have a lower chance of surviving a heart attack than non-smokers, according to new data compiled by researchers at Jordan University of Science and Technology in Irbid.

2 Apr 2022

Groundbreaking collaborative work defines the risk of SARS-CoV-2 variants on immune protection

In a paper in the journal Nature, Los Alamos National Laboratory scientists Bette Korber, Hyejin Yoon, Will Fischer and James Theiler, among nearly 130 authors from institutions around the world, describe their groundbreaking collaborative work, "Defining the risk of SARS-CoV-2 variants on immune protection."

1 Apr 2022

Researchers explore a novel method to isolate monoclonal antibodies from COVID-19 convalescents infected with SARS-CoV-2 variants

Researchers developed a novel high-throughput method to obtain monoclonal antibodies from COVID-19 individuals infected with SARS-CoV-2 ancestral strain Wuhan-Hu-1 and the Beta or Gamma variants.

1 Apr 2022

Study explores molecular mechanisms underlying SARS-CoV-2 infection of macrophages and the induction of pro-inflammatory cytokines

Researchers examined the role of sialic acid-binding immunoglobulin-type lectins-1, a myeloid cell-specific receptor, in facilitating SARS-CoV-2 infection of ACE2-deficient macrophages and its effect on pro-inflammatory cytokine expression.

1 Apr 2022

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

A team of international scientists has recently isolated and characterized pan-coronavirus neutralizing antibodies from individuals with pre-existing immunity against SARS-CoV-2.

1 Apr 2022

The effects of prolonged sleep restriction on energy intake, energy expenditure, and regional fat storage in healthy individuals

A new study provides insights into how experimentally-induced sleeplessness affects body fat when the subject is provided access to food.

1 Apr 2022

No evidence of SARS-CoV-2 in the U.K.'s wild deer population

A new study accepted for publication in the journal Transboundary and Emerging Diseases assesses the potential exposure of U.K. deer to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since studies have shown the spill-over of SARS-CoV-2 infections to the Northern American white-tailed deer. If there is a spill-over, wild deer species can act as reservoirs of SARS-CoV-2 with the possibility of the emergence of new variants.

31 Mar 2022

NIH program provides a real-time risk assessment of variants of SARS-CoV-2

Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vaccine-induced immunity.

31 Mar 2022

Therapeutic antibodies against filoviruses including Ebola and Marburg

Researchers discuss the development and structural characterization of therapeutic monoclonal antibodies targeting the surface glycoprotein of filoviruses.

31 Mar 2022

The mucosal antibody response to SARS-CoV-2

Researchers determine mucosal SARS-CoV-2-specific antibody levels and their neutralizing effect in pediatric and adult patients.

31 Mar 2022

Protein News and Research

Further Reading

Study shows SARS-CoV-2 antibodies persist for one-year post-infection with protection from other variants

Evidence SARS-CoV-2 undergoes ADAR-mediated A-to-I RNA editing in human cells

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

Natural compound found in cardamom shows promise for treating triple-negative breast cancer

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

Multi-mineral supplement could help reduce downstream consequences of fatty liver disease

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Analysis of antioxidants, stress markers in the blood could lead to new diagnostic tool for breast cancer

Smokers have lower odds of surviving a heart attack than non-smokers

Groundbreaking collaborative work defines the risk of SARS-CoV-2 variants on immune protection

Researchers explore a novel method to isolate monoclonal antibodies from COVID-19 convalescents infected with SARS-CoV-2 variants

Study explores molecular mechanisms underlying SARS-CoV-2 infection of macrophages and the induction of pro-inflammatory cytokines

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

The effects of prolonged sleep restriction on energy intake, energy expenditure, and regional fat storage in healthy individuals

No evidence of SARS-CoV-2 in the U.K.'s wild deer population

NIH program provides a real-time risk assessment of variants of SARS-CoV-2

Therapeutic antibodies against filoviruses including Ebola and Marburg

The mucosal antibody response to SARS-CoV-2

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo